

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Caroline Ospelt
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2022 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Viewpoint

- 1203** Developing guidelines for ultrarare rheumatic disorders: a bumpy ride
D Piskin, M Romano, D Aleitaha, B M Feldman, R Goldbach-Mansky, L Carmona, E Demirkaya

Rheumatoid arthritis

- 1206** Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis
S Bugatti, L De Stefano, B D'Onofrio, A Nicosini, E Mauric, M di Lernia, G Sakellariou, E G Favalli, A Manzo, R Caporali, C Montecucco

- 1214** Interferon- α -mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming

F A H Cooles, J Tam, D W Lendrem, N Naamane, C MA Lin, B Millar, N J Maney, A E Anderson, N Thalayasingam, J Diboll, V Bondet, D Duffy, M R Barnes, G R Smith, S Ng, D Watson, R Henkin, A P Cope, L N Reynard, A G Pratt, RA-MAP Consortium, J D Isaacs

- 1224** Distinct stromal and immune cell interactions shape the pathogenesis of rheumatoid and psoriatic arthritis

A Floudas, C M Smith, O Tynan, N Neto, V Krishna, S M Wade, M Hanlon, C Cunningham, V Marzaioli, M Canavan, J M Fletcher, R H Mullán, S Cole, L-Y Hao, M G Monaghan, S Nagpal, D J Veale, U Fearon

Spondyloarthritis

- 1243** MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group

X Baraliakos, M Østergaard, R GW Lambert, I Eshed, P M Machado, S J Pedersen, U Weber, M de Hooge, J Sieper, D Poddubnyy, M Rudwaleit, D van der Heijde, R BM Landewé, W P Maksymowych

- 1252** Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis

M Torguul, V Rios Rodriguez, A Dilbaryan, F Proft, M Protopopov, M Verba, J Rademacher, H Haibel, J Sieper, M Rudwaleit, D Poddubnyy

Systemic lupus erythematosus

- 1260** Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades

A Duarte-García, M Hocaoglu, M Valenzuela-Almada, S-A Osei-Onomah, J Y Dabit, A Sanchez-Rodriguez, S Q Duong, RE Giblon, HE Langenfeld, G S Alarcón, C G Helmick, C S Crowson

- 1267** Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus
T Dörner, Y Tanaka, E R Dow, A E Koch, M Silk, J A Ross Terres, J T Sims, Z Sun, I de la Torre, M Petri

- 1273** Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study

X Yin, K Kim, H Suetsugu, S-Y Bang, L Wen, M Koido, E Ha, L Liu, Y Sakamoto, S Jo, R-X Leng, N Otomo, Y-C Kwon, Y Sheng, N Sugano, M Y Hwang, W Li, M Mukai, K Yoon, M Cai, K Ishigaki, W T Chung, H Huang, D Takahashi, S-S Lee, M Wang, K Karino, S-C Shim, X Zheng, T Miyamura, Y M Kang, D Ye, J Nakamura, C-H Suh, Y Tang, G Motomura, Y-B Park, H Ding, T Kuroda, J-Y Choe, C Li, H Niuro, Y Park, C Shen, T Miyamoto, G-Y Ahn, W Fei, T Takeuchi, J-M Shin, K Li, Y Kawaguchi, Y-K Lee, Y-F Wang, K Amano, D J Park, W Yang, Y Tada, Y L Lau, K Yamaji, Z Zhu, M Shimizu, T Atsumi, A Suzuki, T Sumida, Y Okada, K Matsuda, K Matsuo, Y Kochi, Japanese Research Committee on Idiopathic Osteonecrosis of the Femoral Head, K Yamamoto, K Ohmura, T-H Kim, S Yang, T Yamamoto, B-J Kim, N Shen, S Ikegawa, H-S Lee, X Zhang, C Terao, Y Cui, S-C Bae

Systemic sclerosis

- 1281** Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching

X Yue, J Yin, X Wang, H Heidecke, A M Hackel, X Dong, B Kasper, L Wen, L Zhang, K Schulze-Forster, J Junker, H Grasshoff, A Müller, G Wallukat, I Schimke, J Zeiner, L M Deckstein, N Mertens, A Kerstein-Staehle, J E Hundt, E Kostenis, X Yu, G Riemekasten, F Petersen

Vasculitis

- 1290** Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids

E Estupiñán-Moreno, L Ortiz-Fernández, T Li, J Hernández-Rodríguez, L Ciudad, E Andrés-León, L C Terrou-Camero, S Prieto-González, G Espigol-Frigolé, M C Cid, A Márquez, E Ballestar, J Martín

MORE CONTENTS ►

Member since 2008

.JM00004

This journal is a member of and subscribes to the principles of the

Committee on Publication Ethics

<http://publicationethics.org/>

When you have finished with this please recycle it

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

Autoimmunity

- 1301** Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic component



Y Shirai, Y Nakanishi, A Suzuki, H Konaka, R Nishikawa, K Sonehara, S Namba, H Tanaka, T Masuda, M Yaga, S Satoh, M Izumi, Y Mizuno, T Jo, Y Maeda, T Nii, E Oguro-Igashira, The Biobank Japan Project, T Morisaki, Y Kamatani, S Nakayamada, C Nishigori, Y Tanaka, Y Takeda, K Yamamoto, A Kumano, Y Okada

Osteoporosis

- 1313** Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease

E Wiebe, D Huscher, D Schaumburg, A Palmowski, S Hermann, T Buttgerit, R Biesen, G-R Burnester, Y Palmowski, M Boers, J H Stone, C DeJaco, F Buttgerit

Crystal arthropathies

- 1323** Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis

S K Tedeschi, W Huang, K Yoshida, D H Solomon

Images in rheumatology

- 1330** Clinical image: bone erosions in a young man

L Bastard, B Hagege, M Brehan, H Gouze

Letters

- 1331** Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic

L De Stefano, B D'Onofrio, G Sakellariou, A Manzo, C Montecucco, S Bugatti

- 1332** Cross-reactivity of anti-modified protein antibodies is also present in predisease and individuals without rheumatoid arthritis

S Reijm, A S Brehler, S Rantapää-Dahlqvist, A Kawakami, T Maeda, S Kawashiri, M Tamai, D van der Woude, R E M Toes

- 1334** Sequential interleukin-17/interleukin-23 inhibition in treatment-refractory psoriatic arthritis

D Simon, F Fagni, G Schett

- 1336** Determination of the minimal clinically important difference (MCID) of the physician global assessment (PGA) in SLE

E W Anderson, M Mackay, G Franchin, C Aranow

- 1337** SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection

E Morales, M Galindo

- 1338** Humoral immune-response to a SARS-CoV-2-BNT162b2 booster in inflammatory arthritis patients who received an inactivated virus vaccine

J Durán, P I Burgos, N Le Corre, C Ruiz Tagle, C Martínez-Valdebenito, M Castro, V Metcalfe, P Niemann, M Elvira Balcells

Electronic pages

- e157** More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia

G Ferraccioli

- e158** Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli

E Della-Torre, C Campochiaro, G Cavalli, G De Luca, F Ciceri, A Zangrillo, L Dagna

- e159** Correspondence on: 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Pouletty *et al*

R Pino, A C Izurieta, M Ríos-Barnés, S Ricart, M F De Sevilla, L Monfort, C Launes, I Cano, L Lecina, J Sánchez Manubens, J M Mosquera, I Jordan, J Sánchez de Toledo, M Monsonís, C Esteva, C Muñoz-Almagro, V Fumadó, C Fortuny, J J García García, A Noguera-Julian, J Anton, On behalf of the Kids Corona Project

- e160** Response to: 'Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Pouletty *et al*' by Pino *et al*

N Ouldali, M Pouletty, J Lokmer, C Benzouid, C Beyler, A Deho, U Meinzer, A Faye, I Melki, Great Paris Region (GPR) Kawa-COVID-19 consortium

- e161** Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis

M E Singer, D C Kaelber, M J Antonelli

- e162** Response to: 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer *et al*

M F Ugarte-Gil, M F König, P Korsten, F Berenbaum, A H Kim, J A Sparks

- e163** Correspondence on 'Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist' by Graef *et al*

C H Lo, Y-H Wang, C F Tsai, K C Chan, L C Li, T H Lo, C H Su, J C-C Wei

- e164** Response to: 'Correspondence on 'Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist' by Graef *et al*' by Lo *et al*

A Duarte-García, E R Graef, J W Liew, M F König, A H Kim, J A Sparks

- e165** Correspondence on '2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus' by Aringer *et al*

R Cui, Q Wang, H Zhang, S Wu, X-J Wan, S-M Dai

- e166** Response to: ‘2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus’ by Aringer *et al* by Cui *et al*
M Aringer, K H Costenbader, T Dörner, S R Johnson
- e167** Women’s journey in Mexican rheumatology. Comment on ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga *et al*
I J Colunga-Pedraza, R I Arvizu-Rivera, G Serna-Peña, A L De-Leon-Ibarra, D Alpizar Rodríguez, A Pérez-Villar, M A Reyes Soto, D A Galarza-Delgado
- e168** Response to: ‘Women’s journey in Mexican rheumatology. Comment on ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga *et al*’ by Colunga-Pedraza *et al*
K Monga, J Liew
- e169** Correspondence to ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga and Liew—gender discrepancies at annual EULAR congresses: towards the gap narrowing
P Conigliaro, S L Bosello, C Iannucelli, E Gremese, F R Spinelli, M Vadacca, M S Chimenti
- e170** Response to: ‘Correspondence to ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga and Liew—gender discrepancies at annual EULAR congresses: towards the gap narrowing’ by Conigliaro *et al*
K Monga, J Liew
- e171** Case of postpartum axial spondyloarthritis
K Furuhashi, N Honda, Y Miyoshi, N Yokogawa
- e172** Response to: ‘Case of postpartum axial spondyloarthritis’ by Furuhashi *et al*
A Hoballah, C Lukas, C Leplat, P Taourel, J-B Pialat, N Sans, S Ramos-Pascual, M Saffarini, C Cyteval
- e173** Correspondence on ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’
L Fallon, T V Jones
- e174** Response to: ‘Correspondence on ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Fallon *et al*’
X Baraliakos, L Gossec, I McInnes, A Kerschbaumer, M de Wit, M Dougados, J Primdahl, D van der Heijde, J S Smolen
- e175** Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care
J Molina Collada, J Martínez-Barrio, B Serrano-Benavente, I Castrejón, L R Caballero Motta, L Trives Folguera, J M Álvaro-Gracia
- e176** Response to: ‘Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care’ by Molina Collada *et al*
K SM van der Geest, B Dasgupta
- e177** Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?
K Yamashita, A Takaori-Kondo, K Mizugishi
- e178** Response to: ‘Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?’ by Yamashita *et al*
M Poulety, G Dingulu, N Ouldali, O Corseri, C Ducrocq, U Meinzer, A Faye, C Galeotti, I Mellet, Great Paris Region (GPR) Kawa-COVID-19 consortium
- e179** 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease by Wallace *et al*
B-W Yoo, J J Song, Y-B Park, S-W Lee
- e180** Glucosamine and mortality: a note of caution
R Conway
- e181** Response to: ‘Glucosamine and mortality: a note of caution’ by Conway
Z-H Li, Q-M Huang, W-F Zhong, X-R Zhang, C Mao
- e182** Correspondence to ‘Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study’ by Li *et al*
H-Z Yueh, C-J Yeh, J C-C Wei
- e183** Response to: ‘Correspondence to ‘Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study’ by Li *et al*’ by Yueh *et al*
Z-H Li, W-F Zhong, Q-M Huang, X-R Zhang, C Mao
- e184** Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops *et al*
M Benucci, L Quartuccio, F Li Gobbi, A Damiani, V Grossi, M Infantino, M Manfredi
- e185** Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops *et al*’ by Benucci *et al*
H Schulze-Koops, K Krueger, I V Vallbracht, R Hasseli, A Skapenko
- e186** Terminology and definition of ‘antinuclear antibodies’: history and current debate
R D H Markewitz, K-P Wandinger
- e187** Correction: *Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial*